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Abstract: A 33-year-old white male, 30 days postpancrcatic 
transplant, with a history of juvenile onset diabetes mellitus and 
previous renal transplant, appeared to have cold hemagglutinin 
disease (CHD). He was being treated for acute organ rejection and 
had received two units of red blood cells (RBCs) on postoperative 
day 11, at which time no serum antibodies were detectable. On 
postoperative day 30, serum studies showed an autoanti-I with a 
titer of 512 in 30 percent albumin at 4°C and a maximum thermal 
amplitude of 37°C. The patient had a weakly positive direct anti- 
globulin test (DAT) with only complement detectable on the red 
cells. The patient recovered spontaneously. The etiology of the 
CHD is unclear The use of cyclosporin-A, OKT3 monoclonal anti- 
body, and anti-thymocyte globulin (ATG) to treat acute rejection 
could have played a part. 
Cold hemagglutinin disease (CHD) is a type of cold 
antibody-induced hemolytic anemia where red cell de- 
struction is not always continuous but may be epi- 
sodic. It may occur as an acute or chronic condition. 
The acute form is often secondary to a lymphopro- 
liferative disease or to Mycoplasma pneumoniae in- 
fection. The chronic form is often seen in elderly pa- 
tients with lymphoid malignancies.’ 
The causative antibody is generally a monoclonal 
IgM autoagglutinin that readily binds complement and 
frequently shows specificity within the I blood group 
system.’ Antibody titers greater than 500 at 4°C in al- 
bumin and thermal ranges reactive up to 30°C or 
higher may be seen sup(3) When such a patient is exposed 
to the cold, antibody binds to red cells. 
Treatment of CHD varies according to the severity of 
the disease and may include one or more of the follow- 
ing: avoidance of the cold; the use of immunosup- 
pressive drugs to inhibit autoantibody production; and 
careful “warm”plasmapheresis to remove the autoanti- 
body 
Most patients with CHD tolerate mild or moderate 
anemia and survive many years with minimal discom- 
fort. However, other patients with more severe CHD 
may succumb to progressive anemia, hemosiderosis 
from blood transfusion,* or to an underlying malignant 
disorder. 
We recently had the opportunity to study the devel- 
opment oftransient CHD in a patient who had received 
a pancreatic transplant. 
Case History 
A 33-year-old Caucasian male received a cadaveric 
pancreatic transplant and was subsequently treated for 
acute rejection with cyclosporin A, anti-thymocyte 
globulin (ATG), and OKT3 monoclonal antibody He 
had a history of juvenile onset diabetes mellitus and 
had undergone successful renal transplantation a year 
earlier. A drop in hemoglobin to 6.8 g/dL caused the pa- 
tient’s physician to order two units of RBCs for transfu- 
sion. Pretransfusion testing revealed a potent cold- 
reactive autoantibody and a positive DAT due to 
complement bound to the red cells. 
The patient’s hemoglobin fell again to 6.5 g/dL with 
a total bilirubin of 4.6 mg/dL (2.0 mg/dL indirect). The 
uncorrected reticulocyte count was 4.4 percent. There 
was no hemoglobinuria or hemoglobinemia. A few 
spherocytes, some basophilic stippling, and polychro- 
masia were evident on a peripheral blood smear. 
CHD persisted for less than 10 days. During that pe- 
riod, the patient received four units of RBCs without 
incident. The pancreatic transplant failed and was re- 
moved after 70 days. 
Materials and Methods 
Tests were performed using blood samples collected 
and maintained at 37°C. Standard serologic methods 
were used for ABO and Rh testing.’ DATs were per- 
formed using polyspecific and anti-IgG antihuman 
globulin (Ortho; Raritan, NJ) and anti-C3b, -C3d 
(Gamma; Houston, TX). The tests were read at immedi- 
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ate spin (IS) and after a five-minute incubation at 25°C. 
An ether eluate was prepared by the method ofRubin sup(1) 
and tested with a panel of reagent red cells (BCA; West 
Chester, PA). The saline supernate from the last wash 
was tested in parallel as a control. 
The patient's serum was tested using a panel of 
saline-suspended reagent red cells and read at IS, 25°C, 
and 37°C. A polyspecific reagent was used at the an- 
tiglobulin stage. The method utilizing prewarmed 
samples for panel studies was performed according to 
standard technique.' 
Titration studies were performed using serial dou- 
bling dilutions of the patient's serum in 30 percent bo- 
vine albumin, group 0, I + adult screening cells (BCA) 
and group O, I - cord cells. Tests were incubated for 30 
minutes at 25°C and 4°C, centrifuged, and read for ag- 
glutination. The antibody titer was recorded as the re- 
ciprocal of the last dilution giving a 1 + macroscopic 
reaction. 
Thermal amplitude studies were performed by test- 
ing the patient's serum with reagent screening cells at 
25°C, 30°C, and 37°C. The test serum and reagent red 
cells were incubated separately for 10 minutes at the 
respective temperatures before mixing. After a 
30-minute incubation, the tubes were centrifuged and 
read for agglutination, washed x4 with 37°C saline, and 
tested with anti-IgG and anti-C3 reagents. 
For the Donath-Landsteiner test, a 1-mL aliquot of 
freshly drawn blood from the patient was incubated for 
one hour at 4°C. The sample was then placed in a 37°C 
incubator for a second hour. A control tube with 1 mL 
of the patient's blood was maintained at 37°C for two 
hours. Following the second incubation period, both 
the test and control tubes were centrifuged for five 
minutes at 1,000 X g and the sera were examined for 
hemolysis. 
Results 
The patient typed as group O, Rhsub(o)(D) negative. Di- 
rect antiglobulin tests revealed only complement on 
his red cells (Table 1). An ether eluate was nonreactive 
with a panel of reagent red cells. 
The patient's serum reacted with all reagent red 
cells tested at 4°C, 25°C, and 37°C, and at the indirect 
antiglobulin phase. Using a prewarmed technique, the 
antibody was nonreactive at the antiglobulin phase 
using polyspecific antihuman globulin. In titration 
studies (Table 2), the antibody reacted to a higher titer 
with adult I + and autologous red cells than with cord 
I - red cells, suggesting an autoanti-I specificity In 
tests for thermal amplitude, the patient's serum agglu- 
tinated and bound complement to reagent red cells at 
25°C, 30°C, and 37°C. The Donath-Landsteiner test for 
detection of a biphasic hemolysin was negative. 
Table 1. 












Titration studies in 30 percent bovine albumin 
Type of RBC 25°C 4°C 
Adult I+ 32 512 
Cord I - 2 128 
Auto 8 512 
Discussion 
Clinical data and serologic testing of this patient's 
blood suggested a diagnosis of CHD. Some characteris- 
tic serologic findings included a positive DAT due to 
complement only, an autoanti-I with a titer greater 
than 500 at 4°C, and maximum thermal range of anti- 
body activity above 30°C. 
The pathological autoantibody in CHD differs sero- 
logically from the benign form of antoanti-I that can 
be demonstrated in  the serum of many hema- 
tologically normal adult individuals. The latter usually 
have titers of <64 at 4°C and thermal ranges <25°C.sup(2)A 
negative Donath-Landsteiner test ruled out an IgG bi- 
phasic hemolysin diagnostic of a rare type of antibody- 
induced hemolytic anemia, paroxysmal cold hemoglo- 
binuria (PCH). 
The etiology of CHD in this case is unclear, and the 
role played by the administration of cyclosporin-A, 
OKT3 monoclonal antibody, or ATG for organ rejection 
is unknown. Future reports of CHD in transplant pa- 
tients may reveal a causal relationship. 
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Readers familiar with John Judd‘s Handbook of Sero- 
logical Techniques for Use in Investigative Im- 
munohematology can only be grateful that he has 
taken the time and trouble to update and improve this 
useful volume and to shorten its title. Here at last, in a 
simple format, is a comprehensive list of blood bank 
procedures useful for problem solving. It includes 
everything from routine procedures to research meth- 
ods such as monocyte assays and enzyme-linked an- 
tiglobulin tests. 
The book is divided into 14 sections that include 
procedures for antibody identification, the use of en- 
zymes, elutions, the investigation of autoantibodies, 
and drug-induced antibodies. There are sections on 
high-titer, low-avidity antibodies, hemolytic disease of 
the newborn, ABO typing problems, polyagglutina- 
tion, micromethods, the use of cell separation tech- 
niques, reagent preparation and storage, and a miscella- 
neous section of unusual procedures that would, at the 
very least, allow the blood banker to determine if and 
when he or she would need to use these special tech- 
niques. There is also a useful directory for equipment, 
supplies, and reagents. 
Each section begins with introductory remarks, and 
each step-by-step procedure includes its primary appli- 
cation, materials needed, interpretation, and notes. 
There is also suggested reading and some references, 
although the references, in most cases, do not refer to 
any specific area of the text. 
Anyone who has labored over a procedure manual 
cannot help but appreciate the detail and thorough na- 
ture of this manual. The methods described in it are, of 
course, not the only possible ones, but they are meth- 
ods that are used by workers with extensive experi- 
ence. 
There are a number of useful charts and tables, espe- 
cially the ones on the serologic characteristics of blood 
group antibodies, the selection of antigen-negative 
blood, and a list of drugs associated with drug-induced 
hemolytic anemia. Some of the procedures refer the 
user back to earlier procedures, but given the nature of 
blood bank methods, this is understandable and does 
save space. The ring binding and cover are appropriate 
for a book that is designed to be used at the bench. The 
computer-printed typeface is a little hard to read, but 
this has allowed a very useful book to be published rap- 
idly and at a reasonable cost. 
To an experienced technologist, this book would be 
a useful how-to manual; however, as the author warns, 
the book is not a detailed treatise on blood group serol- 
ogy; the novice problem solver would do well to use 
the listed references at the end of each section as well 
as to pay particular attention to the “Interpretation” 
and “Notes” sections. Blood bank educators should not 
feel that the book is too detailed for their students even 
though its very comprehensiveness is overwhelming. 
It should remain an up-to-date resource for blood 
bankers for many years to come. 
Ruth Mougey, MT(ASCP)SBB 
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